Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies

NCT05047536 is registered in ClinicalTrials.gov with Kezar Life Sciences, Inc. as lead sponsor.

NCT NCT05047536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05047536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies
Lead sponsor
Kezar Life Sciences, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2021
Completion date
January 17, 2025
Enrollment
61 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic solid tumor